Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000950170-23-053818

Options or other derivatives

  • Chief Executive Officer acquired 77,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2023-10-13 Grant or award · Stock Option (Right to Buy) +52,500 52,500 D: show line 1 in the form
Kulkarni Samarth Chief Executive Officer 2023-10-13 Grant or award · Restricted Stock Unit +25,000 25,000 D: show line 2 in the form
Loading xslF345X05/ownership.xml…